Meno-Eze

Main information

Documents

Localization

  • Available in:
  • Meno-Eze
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 221345
  • Last update:
  • 08-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

221345

Meno-Eze

ARTG entry for

Medicine Listed

Sponsor

Vitex Pharmaceuticals Pty Ltd

Postal Address

PO Box 134,HOXTON PARK, NSW, 2171

Australia

ARTG Start Date

17/03/2014

Product category

Medicine

Status

Active

Approval area

Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in

the list of 'Colourings permitted in medicines for oral use'.

All products containing Cimicifuga racemosa must comply with the following condition of listing by carrying the label statement - Warning: In very rare

cases, black cohosh has been associated with liver failure. If you are experiencing yellowing of the skin or whites of the eyes, dark urine, nausea,

vomiting, unusual tiredness, weakness, stomach or abdominal pain, and/or loss of appetite, you should stop using this product and see your doctor.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine,

(b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is

sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be

kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records

to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted

in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office

of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors

of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified

of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine

outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National

Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. Meno-Eze

Product Type

Single Medicine Product

Effective date

17/03/2014

Warnings

Warning: In very rare cases, black cohosh has been associated with liver failure. If you are experiencing yellowing of the skin or whites of the eyes, dark

urine, nausea, vomiting, unusual tiredness, weakness, stomach or abdominal pain, and/or loss of appetite, you should stop using this product and see

your doctor.

Standard Indications

Aids, assists or helps in the maintenance or improvement of general well-being.

Specific Indications

No Specific Indications included on Record

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1. Formulation 1

Dosage Form

Tablet, film coated

Route of Administration

Oral

Visual Identification

Active Ingredients

Actaea racemosa

91 mg

Public Summary

Page 1 of

Produced at 26.11.2017 at 12:57:55 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

Equivalent: Actaea racemosa (Dry)

546 mg

Aesculus hippocastanum

20 mg

Equivalent: Aesculus hippocastanum (Dry)

120 mg

Angelica polymorpha

25 mg

Equivalent: Angelica polymorpha (Dry)

100 mg

Dioscorea villosa

10 mg

Equivalent: Dioscorea villosa (Dry)

100 mg

Glycine max

13.6 mg

Equivalent: Glycine max (Dry)

2.176 g

Glycyrrhiza uralensis

20 mg

Equivalent: Glycyrrhiza uralensis (Dry)

100 mg

Pueraria lobata

6 mg

Equivalent: Pueraria lobata (Dry)

60 mg

Trifolium pratense

250 mg

Equivalent: Trifolium pratense (Dry)

1000 mg

Vitex agnus-castus

10 mg

Equivalent: Vitex agnus-castus (Dry)

100 mg

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 2 of

Produced at 26.11.2017 at 12:57:55 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information